<span class="word">Evaluation <span class="word">of <span class="word">Plasma <span class="word">Catestatin <span class="word">Levels <span class="word">in <span class="word">Patients <span class="word">with <span class="word">Heart <span class="word">Failure

  1. Galip Buyukturan
  2. Remzi Ekici
  3. Ismail Erturk
  4. Birol Yıldız
  5. Ramazan Acar
  6. Taner Ozgurtas
  7. Fevzi Nuri Aydın
  8. Kenan Saglam

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

Introduction: Heart failure (HF) is a commonly encountered fatal clinical condition. Catestatin is a peptide produced by the breakdown of chromogranin A and inhibits catecholamine secretion. The main goal of this study is to identify the difference between catestatin levels in patients at without and with different stages of HF. It is important to determine catestatin’s relationship with pro-B-type natriuretic peptide (proBNP) and left ventricular ejection fraction (LVEF), that are used to identify HF and as well as other laboratory findings in order to better understand the contribution of catestatin. Materials-Methods: Sixty HF patients with LVEF&lt; %45 and 53 matching control patients of factors that can impact catestatin level were included in the study. Plasma samples of these patients and controls were simultaneously collected in tube containing a drop of aprotinin (proteinase inhibitor). Plasma catestatin levels were measured by using enzyme-linked immunosorbent assay method. Results: The study findings showed that catestatin levels of HF patients (45.46±16.69 ng/ml) were significantly higher than that of patients without (37.15±16.36 ng/ml) (t=2.69, p&lt; 0.05) and that the catestatin level increases as the HF stage progresses (J-T=2.19; p&lt; 0.05). Catestatin level is found to be correlated positively with proBNP (r=0.241; p&lt; 0.05), and inversely with LVEF (r=-0.19; p&lt; 0.05). The area under the ROC curve calculated in order to demonstrate catestatin’s diagnostic adequacy in heart failure was 0.635. Discussion: Catestatin is considered an indicator of HF and it seems reasonable to use it for diagnosis and follow-up as it increases with disease severity.

Article activity feed

  1. PREreview

    This Zenodo record is a permanently preserved version of a Structured PREreview. You can view the complete PREreview at https://prereview.org/reviews/18788364.

    Does the introduction explain the objective of the research presented in the preprint? Yes
    Are the methods well-suited for this research? Somewhat appropriate
    Are the conclusions supported by the data? Somewhat supported
    Are the data presentations, including visualizations, well-suited to represent the data? Somewhat appropriate and clear
    How clearly do the authors discuss, explain, and interpret their findings and potential next steps for the research? Very clearly
    Is the preprint likely to advance academic knowledge? Somewhat likely
    Would it benefit from language editing? No
    Would you recommend this preprint to others? Yes, but it needs to be improved
    Is it ready for attention from an editor, publisher or broader audience? Yes, after minor changes

    Competing interests

    The author declares that they have no competing interests.

    Use of Artificial Intelligence (AI)

    The author declares that they did not use generative AI to come up with new ideas for their review.

  2. Version published to 10.20944/preprints202602.1607.v1